Clinical evaluation of lacunar infarction and branch atheromatous disease.
Taizen Nakase, Shotaroh Yoshioka, Masahiro Sasaki...
https://pubmed.ncbi.nlm.nih.gov/22133744/Actively Recruiting
Led by Sigmund Freud PrivatUniversitat · Updated on 2026-07-16
462
Participants Needed
8
Research Sites
N/A
Total Duration
Branch Atheromatous Disease BAD is a type of stroke caused by atherosclerotic blockage in deep brain arteries, such as the lenticulostriate, paramedian pontine, and anterior choroidal arteries. BAD often leads to early neurological worsening, especially motor problems, which increase disability. Despite its importance, BAD is not well represented in common stroke classifications, resulting in limited evidence and unclear treatment approaches. This study aims to compare the effectiveness and safety of intravenous thrombolysis IVT with single or dual antiplatelet therapy SAPT and DAPT in patients with BAD-related stroke and to explore how early blood pressure changes affect neurological outcomes. The study is an international, multicenter, retrospective observational cohort including patients treated between 2010 and 2025 who have BAD confirmed by specific MRI patterns in the affected brain arteries. Patients are grouped based on whether they received IVT or antiplatelet therapy during acute stroke care, with data collected on clinical features, imaging, treatments, and blood pressure changes. The study adheres to STROBE guidelines and uses statistical methods to adjust for differences between groups and analyze outcomes. Participants data include neurological status assessments, imaging results, blood pressure monitoring, and treatment details. Primary outcomes measured are functional recovery at three months, early neurological decline within 24-48 hours, and symptomatic brain bleeding. The study evaluates these outcomes using standardized scales like the modified Rankin Scale and NIH Stroke Scale. Results aim to provide evidence to guide treatment choices for BAD strokes and understand the influence of blood pressure variability on patient recovery.
CONDITIONS
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
J
Julian Frederic Hotz, DDr.
M
Marek Sykora, Prof. Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sigmund Freud PrivatUniversitat
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote review)
Duration - Up to 15 years (2010-2025)
Researchers review medical records, brain MRI scans, treatment details, blood pressure data, and clinical outcomes retrospectively from participating centers.
No participant visits required; data is collected from existing records
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Taizen Nakase, Shotaroh Yoshioka, Masahiro Sasaki...
https://pubmed.ncbi.nlm.nih.gov/22133744/Shinichiro Uchiyama, Kazunori Toyoda, Kazuo Kitagawa...
https://pubmed.ncbi.nlm.nih.gov/31132967/Luca Petrone, Stefania Nannoni, Alessandra Del Bene...
https://pubmed.ncbi.nlm.nih.gov/26671513/Lixin Zhou, Ming Yao, Bin Peng...
https://pubmed.ncbi.nlm.nih.gov/30356780/L R Caplan
https://pubmed.ncbi.nlm.nih.gov/2671793/H P Adams, B H Bendixen, L J Kappelle...
https://pubmed.ncbi.nlm.nih.gov/7678184/Ewgenia Barow, Florent Boutitie, Bastian Cheng...
https://pubmed.ncbi.nlm.nih.gov/30907934/Bin Liu, Hong Zhang, Rong Wang...
https://pubmed.ncbi.nlm.nih.gov/32459110/May Wai-Mei Kwan, Windsor Mak, Raymond Tak-Fai Cheung...
https://pubmed.ncbi.nlm.nih.gov/21277587/Min-Gyu Park, Eun Hye Oh, Baik-Kyun Kim...
https://pubmed.ncbi.nlm.nih.gov/27452127/Sigmund Freud PrivatUniversitat
Lead Sponsor